Revenue

9 Months Ended

Sep. 30, 2025

Revenue Recognition [Abstract]

Revenue

3. Revenue

Net sales by geography are as follows (in millions):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
United States	$	1,164.0	$	1,052.3	$	3,451.4	$	3,257.7
International		837.3		771.9		2,536.3		2,397.7
Total	$	2,001.4	$	1,824.2	$	5,987.7	$	5,655.4

Net sales by product category are as follows (in millions):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
Knees	$	792.4	$	745.1	$	2,411.2	$	2,334.3
Hips		506.2		481.5		1,538.1		1,479.1
S.E.T.		541.5		454.2		1,562.6		1,376.4
Technology & Data, Bone Cement and Surgical		161.3		143.4		475.9		465.6
Total	$	2,001.4	$	1,824.2	$	5,987.7	$	5,655.4

S.E.T. includes sales from our Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic ("CMFT") product categories.

This net sales presentation differs from our reportable operating segments, which are based upon our senior management organizational structure and how we allocate resources toward achieving operating profit goals. Each of our reportable operating segments sells all the product categories noted above. Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings.